Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA

<i>Staphylococcus aureus</i> is well-recognized to cause debilitating bacterial infections that are difficult to treat due to the emergence of antibiotic resistance. As such, there is a need to develop new antimicrobials for the therapeutic intervention of <i>S. aureus</i> di...

Full description

Bibliographic Details
Main Authors: Michaelle Chojnacki, Xufeng Cao, Daniel P. Flaherty, Paul M. Dunman
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/10/4/369
_version_ 1797539364081762304
author Michaelle Chojnacki
Xufeng Cao
Daniel P. Flaherty
Paul M. Dunman
author_facet Michaelle Chojnacki
Xufeng Cao
Daniel P. Flaherty
Paul M. Dunman
author_sort Michaelle Chojnacki
collection DOAJ
description <i>Staphylococcus aureus</i> is well-recognized to cause debilitating bacterial infections that are difficult to treat due to the emergence of antibiotic resistance. As such, there is a need to develop new antimicrobials for the therapeutic intervention of <i>S. aureus</i> disease. To that end, <i>S. aureus</i> RnpA is an essential enzyme that is hypothesized to participate in two required cellular processes, precursor tRNA (ptRNA) maturation and mRNA degradation. Corresponding high throughput screening campaigns have identified the phenylcarbamoyl cyclic thiopenes as a chemical class of RnpA inhibitors that display promising antibacterial effects by reducing RnpA ptRNA and mRNA degradation activities and low human cell toxicity. Herein, we perform a structure activity relationship study of the chemical scaffold. Results revealed that the cycloalkane ring size and trifluoroacetamide moiety are required for antibacterial activity, whereas modifications of the para and/or meta positions of the pharmacophore’s phenyl group allowed tuning of the scaffold’s antimicrobial performance and RnpA inhibitory activity. The top performing compounds with respect to antimicrobial activity also did not exhibit cytotoxicity to human cell lines at concentrations up to 100 µM, greater than 100-fold the minimum inhibitory concentration (MIC). Focused studies of one analog, RNP0012, which exhibited the most potent antimicrobial and inhibition of cellular RnpA activities revealed that the compound reduced bacterial burden in a murine model of <i>S. aureus</i> disease. Taken together, the results presented are expected to provide an early framework for optimization of next-generation of RnpA inhibitor analogues that may represent progenitors of a new class of antimicrobials.
first_indexed 2024-03-10T12:44:58Z
format Article
id doaj.art-dde28886aa6a442f94afb701927e810d
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-10T12:44:58Z
publishDate 2021-03-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-dde28886aa6a442f94afb701927e810d2023-11-21T13:36:22ZengMDPI AGAntibiotics2079-63822021-03-0110436910.3390/antibiotics10040369Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpAMichaelle Chojnacki0Xufeng Cao1Daniel P. Flaherty2Paul M. Dunman3Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642, USADepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University 575 Stadium Mall Dr., West Lafayette, IN 47907, USADepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University 575 Stadium Mall Dr., West Lafayette, IN 47907, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642, USA<i>Staphylococcus aureus</i> is well-recognized to cause debilitating bacterial infections that are difficult to treat due to the emergence of antibiotic resistance. As such, there is a need to develop new antimicrobials for the therapeutic intervention of <i>S. aureus</i> disease. To that end, <i>S. aureus</i> RnpA is an essential enzyme that is hypothesized to participate in two required cellular processes, precursor tRNA (ptRNA) maturation and mRNA degradation. Corresponding high throughput screening campaigns have identified the phenylcarbamoyl cyclic thiopenes as a chemical class of RnpA inhibitors that display promising antibacterial effects by reducing RnpA ptRNA and mRNA degradation activities and low human cell toxicity. Herein, we perform a structure activity relationship study of the chemical scaffold. Results revealed that the cycloalkane ring size and trifluoroacetamide moiety are required for antibacterial activity, whereas modifications of the para and/or meta positions of the pharmacophore’s phenyl group allowed tuning of the scaffold’s antimicrobial performance and RnpA inhibitory activity. The top performing compounds with respect to antimicrobial activity also did not exhibit cytotoxicity to human cell lines at concentrations up to 100 µM, greater than 100-fold the minimum inhibitory concentration (MIC). Focused studies of one analog, RNP0012, which exhibited the most potent antimicrobial and inhibition of cellular RnpA activities revealed that the compound reduced bacterial burden in a murine model of <i>S. aureus</i> disease. Taken together, the results presented are expected to provide an early framework for optimization of next-generation of RnpA inhibitor analogues that may represent progenitors of a new class of antimicrobials.https://www.mdpi.com/2079-6382/10/4/369<i>Staphylococcus aureus</i>antibioticRnpAmRNA degradationptRNA processing
spellingShingle Michaelle Chojnacki
Xufeng Cao
Daniel P. Flaherty
Paul M. Dunman
Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA
Antibiotics
<i>Staphylococcus aureus</i>
antibiotic
RnpA
mRNA degradation
ptRNA processing
title Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA
title_full Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA
title_fullStr Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA
title_full_unstemmed Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA
title_short Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity against <i>Staphylococcus aureus</i> RnpA
title_sort optimization of 2 acylaminocycloalkylthiophene derivatives for activity against i staphylococcus aureus i rnpa
topic <i>Staphylococcus aureus</i>
antibiotic
RnpA
mRNA degradation
ptRNA processing
url https://www.mdpi.com/2079-6382/10/4/369
work_keys_str_mv AT michaellechojnacki optimizationof2acylaminocycloalkylthiophenederivativesforactivityagainstistaphylococcusaureusirnpa
AT xufengcao optimizationof2acylaminocycloalkylthiophenederivativesforactivityagainstistaphylococcusaureusirnpa
AT danielpflaherty optimizationof2acylaminocycloalkylthiophenederivativesforactivityagainstistaphylococcusaureusirnpa
AT paulmdunman optimizationof2acylaminocycloalkylthiophenederivativesforactivityagainstistaphylococcusaureusirnpa